Immunome, Inc.
IMNM · United States
Share price · IMNM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IMNM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Nov 2026+7.6%
- 13 Oct 2026-8.2%
Nothing announced by IMNM that day or the session before.
- 6 Oct 2026-8.8%
- 24 Sep 2026-7.8%
Nothing announced by IMNM that day or the session before.
- 12 Aug 2026+6.6%
- 4 Aug 2026+8.9%
Nothing announced by IMNM that day or the session before.
- 2 Jul 2026+9.9%
Nothing announced by IMNM that day or the session before.
- 22 May 2026-5.7%
Nothing announced by IMNM that day or the session before.
- 21 May 2026+6.6%
Nothing announced by IMNM that day or the session before.
- 20 May 2026+9.5%
Nothing announced by IMNM that day or the session before.
Share of unusual movement by asset
For each asset, the share of IMNM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Varegacestatevents and moves
| 4 | shown from 8 days |
IM-1021events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 6% |
| Other company news (earnings, financing, releases naming no asset) | — | 9% |
| Sessions with no dated event | — | 85% |
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | Gamma-secretase (presenilin complex)Small molecule | Soft Tissue Sarcoma Desmoid Tumors | |
| Phase 1 | ROR1Antibody–drug conjugate | Solid Tumors Advanced ROR1-Expressing Solid Tumors and Lymphomas | |
| Phase 1 | Undisclosed / early pipelineAntibody–drug conjugate | Non-Small Cell Lung Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $70M | $213M+ $249M short-term inv. | $86M-$61M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $60M | $218M+ $302M short-term inv. | $73M-$62M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $46M | $583M | $54M-$59M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $49M | $273M+ $0 short-term inv. | $57M-$41M operating cash flow | report ↗ |
| 2025-Q2 | $4.0M | $40M | $144M+ $124M short-term inv. | $43M-$49M operating cash flow | report ↗ |
| 2025-Q1 | $2.9M | $37M | $258M+ $60M short-term inv. | $42M-$53M operating cash flow | report ↗ |
| 2024-Q3 | $2.9M | $37M | $156M+ $85M short-term inv. | $47M-$34M operating cash flow | report ↗ |
| 2024-Q2 | $2.4M | $29M | $165M+ $113M short-term inv. | $36M-$23M operating cash flow | report ↗ |
| 2024-Q1 | $1.0M | $15M | $270M+ $40M short-term inv. | $129M-$11M operating cash flow | report ↗ |
| 2023-Q3 | $3.6M | $3.8M | $91M | $4.3M-$8.6M operating cash flow | report ↗ |
| 2023-Q2 | $4.3M | $5.7M | $39M | $5.6M-$5.7M operating cash flow | report ↗ |
| 2023-Q1 | $2.4M | $3.9M | $45M | $4.3M$24M operating cash flow | report ↗ |
| 2022-Q3 | — | $5.2M | $27M | $8.5M-$7.6M operating cash flow | report ↗ |
| 2022-Q2 | — | $5.7M | $35M | $8.9M-$8.1M operating cash flow | report ↗ |
| 2022-Q1 | — | $8.1M | $43M | $12M-$6.4M operating cash flow | report ↗ |
| 2021-Q3 | — | $4.5M | $56M | $7.7M-$4.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $6.9M | $177M | $654M+ $0 short-term inv. | $53M-$191M operating cash flow | report ↗ |
Immunome reported full-year 2025 revenue of $6.94M, down 23.2% YoY, with an R&D spend of $177.29M, up 36.9% YoY. Cash and equivalents totaled $653.69M, and the company posted a net loss of $212.39M.
Management expects current cash to fund operations into 2028. An NDA submission for varegacestat in desmoid tumors is planned for 2Q 2026 following positive Phase 3 RINGSIDE results, initial IM-1021 data are expected in 2026, and three IND submissions for solid tumor-targeted ADC programs are planned during the year. A December 2025 underwritten public offering raised $460.5M in gross proceeds.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $9.0M | $130M | $143M+ $74M short-term inv. | $73M-$111M operating cash flow | report ↗ |
| 2023-FY | $14M | $23M | $99M+ $39M short-term inv. | $27M-$7.6M operating cash flow | report ↗ |
| 2022-FY | — | $23M | $20M | $9.2M-$29M operating cash flow | report ↗ |
| 2021-FY | — | $14M | $49M | $6.2M-$18M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 11 purchases ($2.3M), 28 sales ($27.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-11 | Higgins Jack · Chief Scientific Officer | Option exercise | 18,000 | $1.35 | $24K | Form 4 |
| 2026-09-11 | Higgins Jack · Chief Scientific Officer | Open-market sale | 13,200 | $25.32 | $334K | Form 4 |
| 2026-09-11 | Higgins Jack · Chief Scientific Officer | Gift | 8,800 | — | — | Form 4 |
| 2026-09-11 | Higgins Jack · Chief Scientific Officer | Option exercise (derivative) | 18,000 | — | — | Form 4 |
| 2026-08-12 | Barchas Isaac · director | Open-market sale | 11,048 | $27.25 | $301K | Form 4 |
| 2026-08-11 | Barchas Isaac · director | Open-market sale | 62,291 | $26.23 | $1.6M | Form 4 |
| 2026-08-10 | Barchas Isaac · director | Open-market sale | 10,125 | $26.07 | $264K | Form 4 |
| 2026-08-07 | Barchas Isaac · director | Open-market sale | 15,248 | $26.06 | $397K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 199 reporting institutions held 116.7M shares ($2.1B, 98.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 16,969,954 | $371.1M |
| 2 | BlackRock, Inc. | 8,168,674 | $178.6M |
| 3 | Redmile Group, LLC | 5,558,885 | $121.6M |
| 4 | STATE STREET CORP | 5,399,901 | $118.1M |
| 5 | PRIMECAP MANAGEMENT CO/CA/ | 4,788,231 | $104.7M |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 4,731,977 | $103.5M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 4,429,697 | $96.9M |
| 8 | Driehaus Capital Management LLC | 4,099,901 | $89.7M |
| 9 | ENAVATE SCIENCES GP, LLC | 3,613,799 | $79.0M |
| 10 | MORGAN STANLEY | 2,841,589 | $62.1M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 2,560,664 | $56.0M |
| 12 | JPMORGAN CHASE & CO | 2,777,836 | $53.6M |
| 13 | SILVERARC CAPITAL MANAGEMENT, LLC | 1,850,278 | $40.5M |
| 14 | Sofinnova Investments, Inc. | 1,701,904 | $37.2M |
| 15 | Woodline Partners LP | 1,575,398 | $34.5M |